MedTrace Logo

Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic Stroke

NCT01673932 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-01-31

No results posted yet for this study

Summary

The study is to assess the safety and possible efficacy of umbilical cord blood mononuclear cells (UCBMC) treatment of chronic ischemic stroke.

Conditions

Interventions

BIOLOGICAL

UCBMC

Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site

PROCEDURE

surgery

Sponsors & Collaborators

  • Chinese University of Hong Kong

    collaborator OTHER

  • The University of Hong Kong

    collaborator OTHER

  • Prince of Wales Hospital, Shatin, Hong Kong

    collaborator OTHER

  • Queen Mary Hospital, Hong Kong

    collaborator OTHER

  • StemCyte, Inc.

    collaborator INDUSTRY

  • China Spinal Cord Injury Network

    lead NETWORK

Principal Investigators

  • Waisang Poon, MD · The Chinese University of Hong Kong, Prince of Wales Hospital

  • Gilberto Ka Kit Leung, MD · The University of Hong Kong, Queen Mary Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2018-12-31
Completion
2019-07-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01673932 on ClinicalTrials.gov